How many clinical trials are tracked for graft-versus-host disease?

79 trials are tracked, 4 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

Log in / Sign up

Graft-versus-host disease

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for graft-versus-host disease

79 trials tracked for graft-versus-host disease: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 223 citations.

79Trials tracked

6Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 3 6 Phase 2 60 Phase 1 6 Other / NA 7

Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 223 cited
Phase 3 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed · 153 cited
Phase 3 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed · 114 cited
Phase 3 Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) Completed · 52 cited
Phase 3 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed
Phase 3 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease Completed

Show 44 more trials

Phase 2 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Completed
Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
Phase 2 Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease Completed
Phase 2 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Completed
Phase 2 Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Completed
Phase 2 Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) Completed
Phase 2 Montelukast to Treat Bronchiolitis Obliterans Completed
Phase 2 Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) Completed
Phase 2 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Completed
Phase 2 A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD Completed
Phase 2 Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Completed
Phase 2 A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD Completed
Phase 2 Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Completed
Phase 2 Photopheresis for the Treatment of Acute Graft Versus Host Disease Completed
Phase 2 Dexamethasone Solution and Dexamethasone in Mucolox™ Completed
Phase 2 Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) Completed
Phase 2 Pomalidomide for Chronic Graft-versus-Host Disease Completed
Phase 2 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Completed
Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
Phase 2 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Completed
Phase 2 Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Completed
Phase 2 Itacitinib for Low Risk GVHD Completed
Phase 2 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Completed
Phase 2 Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease Completed
Phase 2 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD Completed
Phase 2 Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant Completed
Phase 2 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed
Phase 2 Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease Completed
Phase 2 Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT) Completed
Phase 2 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment Completed
Phase 2 Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant Completed
Phase 2 Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD Completed
Phase 2 Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Completed
Phase 2 Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Completed
Phase 2 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Completed
Phase 2 A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan Completed
Phase 2 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Completed
Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease Completed
Phase 2 Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease Completed
Phase 2 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer Completed
Phase 2 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed
Phase 2 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Completed
Phase 2 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed
Phase 2 Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Completed

Showing the 50 most-cited and recently-updated of 79 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Questions about graft-versus-host disease

Does TCR profiling predict graft-versus-host disease in stem cell transplant patients?

Yes, longitudinal TCR profiling can predict GVHD in stem cell transplant patients, with studies showing AUC values around 0.83 for GVHD prediction.

Full answer →